Revvity is a high-quality life-science tools & diagnostics compounder — immunodiagnostics, reagents, detection instruments and signals software for pharma and clinical labs. Four straight earnings beats, a clean balance sheet (no active ATM, no equity shelf takedown), buyback-funded EPS, and at ~18x forward earnings it is the most reasonably-valued name in its quality cohort. Crucially, the chart is the least-extended of the set: price sits just 0.4% over a freshly-stacking EMA20, with EMA20 > EMA50 > EMA200 newly aligning.StockAnalysis· live
Revvity (formerly the discovery & analytical-solutions side of PerkinElmer) is a focused life-science tools & diagnostics company built around two engines. The Life Sciences segment sells reagents, detection & imaging instruments and the Signals scientific-data software that pharma and academic labs run their R&D on. The Diagnostics segment is anchored by immunodiagnostics, newborn screening and applied genomics — recurring, consumable-heavy revenue with high switching costs.SEC 10-K· 2026
The moat is the classic razor-and-blade tools model: instruments and assays get embedded in lab and clinical workflows, then pull years of consumable and software revenue behind them. Revenue is ~$2.90B TTM with adjusted operating margins around 28%, and management is reshaping the mix — announcing an intent to divest the China Immunodiagnostics business to lift structural margin and reduce geopolitical exposure, at the cost of a near-term EPS trim.Q1'26 release· mai 2026
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $2.90B | +5% YoY |
| Net Income (TTM) | $239.7M | GAAP, divestiture noise |
| EBITDA Margin | ~28% | Healthy |
| Operating Margin (adj.) | 28.4% | Strong |
| ROE | 3.3% | GAAP-depressed |
| Debt / Equity | 0.39 | Conservative |
| Total Debt / EBITDA | 4.3x | M&A-funded |
| Current Ratio | 1.72 | Liquid |
| EPS (adj., FY26 guide) | $5.20 – $5.30 | Post-divestiture |
| Fwd P/E | 18.2x | Reasonable for quality |
| P/E (TTM, GAAP) | 47.7x | D&A + one-offs |
| Analyst Target (avg) | $113 | ~13% upside |
Read the right multiple. The 47.7x trailing GAAP P/E looks nosebleed, but it is distorted by acquisition amortization and divestiture one-offs. The honest lens for a tools/diagnostics compounder is the forward ~18.2x on the $5.41 adjusted-EPS path — a genuine discount to peers like Danaher and Thermo Fisher, which is why the valuation axis holds for an A+.
This is the section where small/mid-cap theses usually break — and where RVTY shines. The cap table is clean: shares outstanding actually fell from 112.28M (Dec 28, 2025) to 111.63M (Apr 5, 2026) as the company executed against a $1B repurchase authorization. There is no active at-the-market (ATM) program, no recent 424B5 equity takedown, and no convertible or warrant overhang. The Feb-2025 S-3ASR on file is a routine automatic universal shelf (Revvity is a well-known seasoned issuer) — boilerplate, not a dilution signal.SEC EDGAR· CIK 31791
| Item | Status | Verdict |
|---|---|---|
| ATM / equity offering | None active | Clean |
| 424B5 equity takedown (LTM) | None | Clean |
| Warrants / convertibles | None outstanding | Clean |
| S-3ASR (Feb 2025) | Routine WKSI shelf | Boilerplate |
| Buyback authorization | $1B (Q3'25) | Float-shrinking |
| Shares: Dec'25 → Apr'26 | 112.28M → 111.63M | -0.6% (reduced) |
No toxic-financing fingerprints, no aggressive boutique underwriters, no mandatory convertibles, no heavy stock-based-comp drag. Buybacks are doing the opposite of dilution — shrinking the share count and amplifying per-share earnings. This is exactly the balance-sheet profile an A+ rating requires.
| RSI (14) | 52.6 |
| Price | $99.66 |
| EMA 20 | $99.27 |
| EMA 50 | $96.50 |
| EMA 200 | $95.45 |
| Extension over EMA20 | +0.4% |
| ATR (14) | $2.27 |
This is the cleanest entry profile in the cohort. Price ($99.66) sits just 0.4% over a freshly-rising EMA20 ($99.27), with EMA20 > EMA50 ($96.50) > EMA200 ($95.45) — a newly-stacking bullish alignment rather than a stretched parabola. RSI 52.6 is dead-neutral, meaning there is no overbought tax to pay on entry and plenty of room before the move gets crowded. ATR $2.27 (~2.3%) gives a defined, structure-based stop. The setup is a controlled pullback-to-trend buy, not a chase.Finviz· live
A diversified, recurring-revenue tools & diagnostics franchise with a clean balance sheet. The principal risks are end-market funding (China + academia) and the near-term EPS dilution from the China Immunodiagnostics divestiture — both manageable, neither structural.
RVTY's risks are end-market (funding cyclicality) and transitional (divestiture timing) — not existential. There is no cash-burn clock, no dilution overhang and no balance-sheet fragility. The downside case is a slower compounder that lags peers for a year, not a structural impairment. That asymmetry is what supports a structure-based stop below the EMA50/200 cluster and an A+ grade.
Buy the pullback into a freshly-stacking trend, not a chase. The buy-limit at $98.45 sits right on the rising EMA20, paying no overbought premium (RSI 52.6) while the longer-term structure (EMA50/200) is turning up underneath. The reward leg targets the prior consolidation high zone (TP1 $112.19, just under the analyst average of $113.64) and a re-test of the 52-week high (TP2 $120.43). With a structure stop below the EMA50/200 cluster (~3 ATR of room, $2.27 ATR), R/R is 2.0 to TP1 and 3.2 to TP2 — comfortably above the 1.5 floor.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from DailyTickers Gateway, Yahoo Finance, StockAnalysis.com, MarketBeat and SEC EDGAR. Accuracy is not guaranteed.